A Randomised controlled trial on the efficacy of topical application of autologous Platelet Rich Plasma(PRP) on graft uptake rate in adults undergoing Type 1 Tympanoplasty for inactive COM mucosal disease

Chronic Otitis Media (COM) is a common ailment in the country and a leading cause of treatable deafness. It is defined as chronic inflammation of the mucosal lining of the middle ear cleft. In the mucosal type of COM, there is a permanent perforation of pars tensa. Surgery in the form of Tympanoplasty is the standard of care of such patients. A common cause of failure of this surgery includes graft failure. Platelet-rich plasma (PRP) is emerging biotechnology and a simple and minimally invasive method to obtain a high concentration of autologous growth factors at sites of healing. The usage of PRP as a topical packing material in Type 1 Tympanoplasty has been reported to enhance the graft uptake and closure rate of perforation as compared to traditional method. However, the data available is limited and no properly conducted RCTs are available to provide evidence of this adjuvant to surgery.

Accordingly, it is hypothesised that using autologous PRP as an adjuvant to standard treatment (type 1 Tympanoplasty) would enhance healing rates and minimise graft failures. The present study will get the much-needed level of evidence to prove a simple and efficacious adjuvant to improve outcomes of this common disorder.